The recent clinical trial (DAWN) suggests that recanalization treatment may be beneficial up to 24 h after stroke onset, thus reopening avenues for development of new therapeutic strategies. Unfortunately, there is a continuous failure of drugs in clinical trials and one of the major reasons proposed for this translational roadblock is the animal models. Therefore, the purpose of this study was to validate a new thromboembolic stroke rat model that mimics the human pathology, and that can be used for evaluating new strategies to save the brain in conditions compatible with recanalization. Stroke was induced by injection of thrombin into the middle cerebral artery. Recombinant tissue-type plasminogen activator (rt-PA) or saline was administrated at 1 h/4 h after stroke onset, and outcome was evaluated after 24 h. Induced ischemia resulted in reproducible cortical brain injuries causing a decrease in neurological function 24 h after stroke onset. Early rt-PA treatment resulted in recanalization, reduced infarct size and improved neurological functions, while late rt-pA treatment showed no beneficial effects and caused hemorrhagic transformation in 25% of the rats. this validated and established model's resemblance to human ischemic stroke and high translational potential, makes it an important tool in the development of new therapeutic strategies for stroke. Stroke continues to be one of the leading causes of death and disability worldwide, costing the world billions of EUR each year 1. In 2016 over 13.6 million people suffered from a stroke, and in over 80% of the cases the stroke was ischemic 2,3. The only proven drug treatment for acute ischemic stroke is thrombolysis induced by the drug recombinant tissue-type plasminogen activator (rt-PA), either alone or combined with the removal of the thrombi/emboli by thrombectomy. Considering that less than 15% of patients received rt-PA (20-40% of efficacy) and that only 5-10% of patients are eligible for the combined treatment (70-80% of efficacy), there is still a need to develop new treatment strategies 4-8. In addition to the low numbers of patients treated and low efficacy rates, thrombolysis is also associated with an increased risk of a hemorrhagic transformation, leading to worsen outcomes and increased mortality 9,10. Many attempts have been made to discover new treatment options. However, even if the majority of therapies showed beneficial results in preclinical studies, none have shown to improve stroke outcomes in humans 11. The "bench-to-bedside" stalemate has been heavily discussed, and one of the recurrent reasons behind this is the experimental stroke models used. Even if it is impossible to mimic human stroke in animals completely, the translational potential will increase significantly by enhancing the resemblance between the preclinical and clinical settings.